ReviewDermatologic clinics2018
Pruritus Associated with Targeted Anticancer Therapies and Their Management.
Review in Dermatologic clinics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.The Journal of urology · 2022Trial
- Targeting Dermatologic Side Effects of Immunotherapy Using Novel Skin Care Products.Journal of Cancer · 2026Article
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies.Biomedicines · 2025Review
- Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma (ccRCC).International journal of molecular sciences · 2025Review
- Dermatologic toxicities related to cancer immunotherapy.Toxicology reports · 2025Article
- Diagnosis and Management of Skin Toxicities in Systemic Treatment of Genitourinary Cancers.Cancers · 2025Review
- Patient perspectives on epidermal growth factor receptor inhibitor-induced skin toxicities: a qualitative study.Frontiers in psychology · 2025Article
- Corticosteroids in lung cancer.Frontiers in drug safety and regulation · 2025Review
- Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients.Breast cancer research and treatment · 2024Article
- Pathogenesis, pathological characteristics and individualized therapy for immune-related adverse effects.Chinese medical journal pulmonary and critical care medicine · 2023Review
- Immune Reactions in Major Types of Oncological Treatment.International journal of molecular sciences · 2023Review
- Cutaneous manifestations associated with immune checkpoint inhibitors.Frontiers in immunology · 2023Review
- Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies.Nature reviews. Drug discovery · 2022Review
- The use of montelukast for pruritus in neurofibromatosis 1.JAAD case reports · 2022Article
- Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.Current oncology (Toronto, Ont.) · 2022Review
- Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review.Cancer treatment reviews · 2022Review
- Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies.Frontiers in oncology · 2022Review
- Immune-related cutaneous adverse events due to checkpoint inhibitors.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2021Review
- Causes of Pruritus in Patients Treated With Immune Checkpoint Inhibitors for Melanomas or Skin Carcinomas.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Targeted anticancer therapies have significantly increased the survival of patients with a variety of malignancies, improving tolerability and treatment duration. The increased lifespan and the expanded use of targeted agents have led to a variety of treatment-related adverse events. Pruritus, a common dermatologic adverse event with various incidences ranging from 2.2% to 47% across different categories of targeted anticancer therapies, has been overlooked. This article reviews the incidence, accompanying skin conditions, possible pathomechanism, and proposed management algorithms of pruritus associated with targeted therapies, including immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.